Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer
Authors:
Open Access
- 15 November 2022
- journal article
- research article
- Published by Elsevier in Cell Reports Medicine
- Vol. 3 (11) , 100815
Abstract
No abstract availableKeywords
Funding Information
- American Association for Cancer Research
- Lustgarten Foundation (SU2C-AACR-PCC-01-18)
This publication has 64 references indexed in Scilit:
- Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancersNature, 2013
- Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose MetabolismCell, 2012
- Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in miceJournal of Clinical Investigation, 2012
- RAS Interaction with PI3K: More Than Just Another Effector PathwayGenes & Cancer, 2011
- Dose Escalation Methods in Phase I Cancer Clinical TrialsJNCI: Journal of the National Cancer Institute, 2009
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersNature Medicine, 2008
- The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathwayCellular Signalling, 2008
- Monitoring Tumor Glucose Utilization by Positron Emission Tomography for the Prediction of Treatment Response to Epidermal Growth Factor Receptor Kinase InhibitorsClinical Cancer Research, 2006
- Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in miceCancer Cell, 2005
- The ‘Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signalingTrends in Biochemical Sciences, 2003